Somatostatin plus Ulinastatin in the Treatment of Severe Acute Pancreatitis and Its Effect on Serum Cytokine Levels

Abstract

Objective. To investigate the effect of somatostatin combined with ulinastatin in the treatment of patients with severe acute pancreatitis and its effect on serum cytokine levels. Methods. This study is a retrospective trial. One hundred patients with severe acute pancreatitis in our hospital between March 2020 and May 2021 were recruited and assigned into the control group (ulinastatin alone) and experimental group (somatostatin plus ulinastatin) according to different treatment methods, 50 cases each. The clinical efficacy and serum cytokine levels of the two groups were compared. Results. Somatostatin plus ulinastatin was associated with a higher total effective rate versus ulinastatin alone ( p < 0.05 ). After treatment, the experimental group observed significantly better interleukin-10 (IL-10), interleukin-18 (IL-18), and tumor necrosis factor-α (TNF-α) when compared with those in the control group ( p < 0.05 ); somatostatin plus ulinastatin resulted in better serum amylase, blood calcium, blood urea nitrogen, blood sugar, and white blood cell count versus ulinastatin alone ( p < 0.05 ). Conclusion. Somatostatin plus ulinastatin is a viable alternative in the treatment of patients with severe acute pancreatitis, with a remarkable efficacy profile. It is worthy of clinical application.

Ulinastatin in the treatment of severe acute pancreatitis: A single-center randomized controlled trial

“…The primary endpoint of this study was 7-d mortality. Additionally, we also evaluated the clinical efficacy, and the specific evaluation methods referred to in the previous literature[ 7 ] included cured, effective, and ineffective. Cured as follows: Clinical symptoms (including fever, abdominal distension, abdominal pain, etc. )…”

“…Although it is generally considered a mild disease with a good prognosis in most AP patients, 15% to 20% of AP patients develop a severe condition with high morbidity and mortality with systemic and local complications[ 5 , 6 ]. Pancreatitis is aggravated by inappropriate treatment, which is responsible for over 25% of mortality associated with severe AP[ 7 , 8 ]. Although surgical treatment is currently the mainstay in clinical practice, a recent meta-analysis confirmed the presence of multiple complications, postoperative body pain, and prolonged postoperative recovery duration after surgical intervention[ 9 ].…”

“…Although surgical treatment is currently the mainstay in clinical practice, a recent meta-analysis confirmed the presence of multiple complications, postoperative body pain, and prolonged postoperative recovery duration after surgical intervention[ 9 ]. More researchers are calling for conservative treatment with drugs, especially for severe AP patients who prefer not to undergo surgery, which might be a good try[ 1 , 5 , 7 , 10 , 11 ].…”

“…Another retrospective study enrolled 78 SAP patients and showed that UTI combined with glutamine is effective in treating severe pancreatitis, which efficiently facilitates the recovery of immune, metabolic, and liver functions[ 5 ]. Yang and Zhao[ 7 ] also reported a retrospective study that enrolled 100 severe AP patients and showed that somatostatin plus UTI is a viable alternative in the treatment of severe AP patients. A meta-analysis of RCTs suggested that UTI demonstrated a favorable benefit in treating acute respiratory distress syndrome patients, but this conclusion has not been verified without a larger sample size of RCTs[ 20 ].…”

Retracted: Somatostatin plus Ulinastatin in the Treatment of Severe Acute Pancreatitis and Its Effect on Serum Cytokine Levels

“…Tis article has been retracted by Hindawi following an investigation undertaken by the publisher [1]. Tis investigation has uncovered evidence of one or more of the following indicators of systematic manipulation of the publication process:…”